ASCO: Alpine reports 61% 'clinical benefit' in early trial of CD28-targeted immuno-oncology drug

Retrieved on: 2021-06-07 14:03:45

Tags for this article:

Click the tags to see associated articles and topics

ASCO: Alpine reports 61% 'clinical benefit' in early trial of CD28-targeted immuno-oncology drug. View article details on hiswai:

Excerpt

But the company is also pursuing one strategy for stimulating CD28 to improve the immune response to cancer—and it has early evidence its plan ...

Article found on: www.fiercebiotech.com